Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: a retrospective cohort study

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a major public health concern since the start of the 2019 pandemic. Although current vaccines protect the general public, individuals with severe immunodeficiencies often exhibit a poor vaccine response and a higher risk of severe and/or persistent disease [1,2]. There are no treatment recommendations for persistent infection in immunocompromised individuals. Attempts with repeated antiviral mono or combination therapy has been described [3].
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Short Communication Source Type: research